Provectus Pharmaceuticals Inc. Announces Completion of Phase 1 Clinical Trial of PV-10 in Recurrent Breast Cancer

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced that it has successfully completed its Phase 1 clinical trial of PV-10 in the treatment of recurrent breast carcinoma.
MORE ON THIS TOPIC